Cargando…

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

SIMPLE SUMMARY: The treatment landscape of advanced prostate cancer (PCa) is constantly improving with the approval of many new therapeutic options. Immunotherapy in PCa has been investigated with disappointing results. This review aims to evaluate the potential role of immunotherapy in both castrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebuzzi, Sara Elena, Rescigno, Pasquale, Catalano, Fabio, Mollica, Veronica, Vogl, Ursula Maria, Marandino, Laura, Massari, Francesco, Pereira Mestre, Ricardo, Zanardi, Elisa, Signori, Alessio, Buti, Sebastiano, Bauckneht, Matteo, Gillessen, Silke, Banna, Giuseppe Luigi, Fornarini, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909751/ https://www.ncbi.nlm.nih.gov/pubmed/35267553 http://dx.doi.org/10.3390/cancers14051245

Ejemplares similares

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Cardiac Metastasis from Prostate Cancer: A Case Study Underlying the Crucial Role of the PSMA PET/CT
por: Gandini, Annalice, et al.
Publicado: (2023)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2023)

The Role of mpMRI in the Assessment of Prostate Cancer Recurrence Using the PI-RR System: Diagnostic Accuracy and Interobserver Agreement in Readers with Different Expertise
por: Bergaglio, Chiara, et al.
Publicado: (2023)

Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
por: Bauckneht, Matteo, et al.
Publicado: (2021)

The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
por: Bauckneht, Matteo, et al.
Publicado: (2020)

Prostate Cancer and Sleep Disorders: A Systematic Review
por: Sparasci, Davide, et al.
Publicado: (2022)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Beyond the Prognostic Value of 2-[(18)F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management
por: Borea, Roberto, et al.
Publicado: (2022)

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
por: Anpalakhan, Shobana, et al.
Publicado: (2023)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
por: Boutros, Andrea, et al.
Publicado: (2022)

The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
por: Turco, Fabio, et al.
Publicado: (2022)

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
por: Ottaviano, Margaret, et al.
Publicado: (2021)

Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences
por: Santoni, Matteo, et al.
Publicado: (2023)

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2022)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
por: Santini, Daniele, et al.
Publicado: (2023)

Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
por: Mollica, Veronica, et al.
Publicado: (2022)

The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
por: De Feo, Maria Silvia, et al.
Publicado: (2023)

Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review
por: Mazzaschi, Giulia, et al.
Publicado: (2022)

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer
por: Mollica, Veronica, et al.
Publicado: (2020)

Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
por: Bauckneht, Matteo, et al.
Publicado: (2022)

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
por: Rescigno, Pasquale, et al.
Publicado: (2022)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
por: Lanfranchi, Francesco, et al.
Publicado: (2023)

Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study
por: Bauckneht, Matteo, et al.
Publicado: (2023)

N-Myc a key gene promoting a worst prostate cancer progression
por: Di Nunno, Vincenzo, et al.
Publicado: (2019)

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
por: Rebuzzi, S.E., et al.
Publicado: (2022)

P1245 Polymorphic Variants of HSD3B1 Gene Confer Different Outcome in Specific Subgroups of Patients Infected With SARS-CoV-2
por: Epistolio, Samantha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f5ecuvb7q241i9138l5c5gmlp5